175 related articles for article (PubMed ID: 32216377)
1.
Li L; Rousseau J; Jaraquemada-Peláez MG; Wang X; Robertson A; Radchenko V; Schaffer P; Lin KS; Bénard F; Orvig C
Bioconjug Chem; 2021 Jul; 32(7):1348-1363. PubMed ID: 32216377
[TBL] [Abstract][Full Text] [Related]
2. H
Kadassery KJ; King AP; Fayn S; Baidoo KE; MacMillan SN; Escorcia FE; Wilson JJ
Bioconjug Chem; 2022 Jun; 33(6):1222-1231. PubMed ID: 35670495
[TBL] [Abstract][Full Text] [Related]
3. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.
Thiele NA; Brown V; Kelly JM; Amor-Coarasa A; Jermilova U; MacMillan SN; Nikolopoulou A; Ponnala S; Ramogida CF; Robertson AKH; Rodríguez-Rodríguez C; Schaffer P; Williams C; Babich JW; Radchenko V; Wilson JJ
Angew Chem Int Ed Engl; 2017 Nov; 56(46):14712-14717. PubMed ID: 28963750
[TBL] [Abstract][Full Text] [Related]
4. Advancing Chelation Chemistry for Actinium and Other +3 f-Elements, Am, Cm, and La.
Stein BW; Morgenstern A; Batista ER; Birnbaum ER; Bone SE; Cary SK; Ferrier MG; John KD; Pacheco JL; Kozimor SA; Mocko V; Scott BL; Yang P
J Am Chem Soc; 2019 Dec; 141(49):19404-19414. PubMed ID: 31794205
[TBL] [Abstract][Full Text] [Related]
5. Computer-Assisted Design of Macrocyclic Chelators for Actinium-225 Radiotherapeutics.
Morgenstern A; Lilley LM; Stein BW; Kozimor SA; Batista ER; Yang P
Inorg Chem; 2021 Jan; 60(2):623-632. PubMed ID: 33213142
[TBL] [Abstract][Full Text] [Related]
6. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
7. [
Li L; Jaraquemada-Peláez MG; Aluicio-Sarduy E; Wang X; Jiang D; Sakheie M; Kuo HT; Barnhart TE; Cai W; Radchenko V; Schaffer P; Lin KS; Engle JW; Bénard F; Orvig C
Inorg Chem; 2020 Feb; 59(3):1985-1995. PubMed ID: 31976659
[No Abstract] [Full Text] [Related]
8. H
Wang X; Jaraquemada-Peláez MG; Rodríguez-Rodríguez C; Cao Y; Buchwalder C; Choudhary N; Jermilova U; Ramogida CF; Saatchi K; Häfeli UO; Patrick BO; Orvig C
J Am Chem Soc; 2018 Nov; 140(45):15487-15500. PubMed ID: 30394734
[TBL] [Abstract][Full Text] [Related]
9. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
10. p-NO
Spreckelmeyer S; Ramogida CF; Rousseau J; Arane K; Bratanovic I; Colpo N; Jermilova U; Dias GM; Dude I; Jaraquemada-Peláez MG; Bénard F; Schaffer P; Orvig C
Bioconjug Chem; 2017 Aug; 28(8):2145-2159. PubMed ID: 28683198
[TBL] [Abstract][Full Text] [Related]
11. Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
13. Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.
Pandya DN; Hantgan R; Budzevich MM; Kock ND; Morse DL; Batista I; Mintz A; Li KC; Wadas TJ
Theranostics; 2016; 6(5):698-709. PubMed ID: 27022417
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.
Wilson JJ; Ferrier M; Radchenko V; Maassen JR; Engle JW; Batista ER; Martin RL; Nortier FM; Fassbender ME; John KD; Birnbaum ER
Nucl Med Biol; 2015 May; 42(5):428-438. PubMed ID: 25684650
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of [
Cortez A; Josefsson A; McCarty G; Shtekler AE; Rao A; Austin Z; Nedrow JR
Nucl Med Biol; 2020; 88-89():62-72. PubMed ID: 32799049
[TBL] [Abstract][Full Text] [Related]
16. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators.
Antczak C; Jaggi JS; LeFave CV; Curcio MJ; McDevitt MR; Scheinberg DA
Bioconjug Chem; 2006; 17(6):1551-60. PubMed ID: 17105236
[TBL] [Abstract][Full Text] [Related]
17. Navigating through the coordination preferences of heavy alkaline earth metals: Laying the foundations for
Franchi S; Madabeni A; Tosato M; Gentile S; Asti M; Orian L; Di Marco V
J Inorg Biochem; 2024 Jul; 256():112569. PubMed ID: 38701687
[TBL] [Abstract][Full Text] [Related]
18. Chelating Rare-Earth Metals (Ln
Hu A; Simms ME; Kertesz V; Wilson JJ; Thiele NA
Inorg Chem; 2022 Aug; 61(32):12847-12855. PubMed ID: 35914099
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
20. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.
Price EW; Zeglis BM; Cawthray JF; Ramogida CF; Ramos N; Lewis JS; Adam MJ; Orvig C
J Am Chem Soc; 2013 Aug; 135(34):12707-21. PubMed ID: 23901833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
